Apogee Therapeutics, Inc. ((APGE)) announced an update on their ongoing clinical study.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Apogee Therapeutics, Inc. is conducting a study titled ‘A Long-term Extension Study to Evaluate the Safety and Efficacy of APG777 in Patients With Atopic Dermatitis Previously Treated With APG777.’ The study aims to assess the long-term safety and efficacy of APG777 in patients with moderate-to-severe atopic dermatitis (AD) who have completed a previous APG777 study. This is significant as it could provide a sustained treatment option for AD patients.
The intervention being tested is APG777, a drug administered via subcutaneous injection. It is designed to maintain or improve the condition of patients with atopic dermatitis by continuing the treatment regimen from a prior study.
The study is interventional, with a non-randomized, sequential intervention model. It employs quadruple masking, meaning the participant, care provider, investigator, and outcomes assessor are all blinded. The primary purpose of this study is treatment-focused.
The study began on May 26, 2025, with the latest update submitted on August 12, 2025. These dates are crucial as they mark the progression and current status of the study, which is still recruiting participants.
This update could positively influence Apogee Therapeutics’ stock performance and investor sentiment, as successful long-term results may enhance the company’s market position in treating atopic dermatitis. Competitors in the dermatology sector will be closely monitoring these developments.
The study is ongoing, and further details can be found on the ClinicalTrials portal.